View abstract

Cet abstract a été assigné à sessions
Type de présentationE-poster
TitreClinical outcomes after switching to Faricimab in patients with prior anti-VEGF therapy, affected by exsudative age-related macular degeneration
ButFaricimab is the first bispecific antibody approved for treating exsudative age-related macular degeneration (eAMD), targeting both, VEGF-A and Angiopoietin-2 (Ang2). This study aims to evaluate functional and anatomical changes following a therapy switch to Faricimab.
MéthodesA retrospective study was conducted on all eAMD patients at the ophthalmology department of the University Medical Center Mainz, Germany who received prior anti-VEGF therapy and were switched to Faricimab between September 2022 and Januar 2024. Changes in central retinal thickness (CRT), macular volume (CRV) in the central 3 mm and visual acuity (logMAR) were assessed, 4 weeks after the first (FU1) and second (FU2) Faricimab series. Significant differences were analyzed using two-sided t-tests.
RésultatsThe study included 26 eyes from 24 patients. The average diagnosis-to-Faricimab switch interval was 4.8 years, with a mean of 34 prior injections. FU1 was 3.4 months and FU2 7.6 months, after the first Faricimab injection. A significant reduction in CRT and CRV (p<0.05) was observed at FU1 and FU2 compared to baseline, with no significant changes between FU1 and FU2. Compared to baseline, no significant changes of logMAR were observed at FU1 or FU2 (p>0.05).
ConclusionAfter switching to Faricimab, anatomical improvements were noted following the first injection series. No functional improvements were observed, though logMAR remained stable. The long-term stability under Faricimab needs to be further evaluated.
Conflit d'intérêtNon
Auteurs 1
NomWOLFRUM
InitialesP
InstitutUniversity Medical Center of the Johannes Gutenberg-University
VilleMainz
Auteurs 2
NomStoffelns
InitialesB
InstitutUniversity Medical Center of the Johannes Gutenberg-University
VilleMainz
Auteurs 3
NomPfeiffer
InitialesN
InstitutUniversity Medical Center of the Johannes Gutenberg-University
VilleMainz
Auteurs 4
NomKorb
InitialesC
InstitutUniversity Medical Center of the Johannes Gutenberg-University
VilleMainz
top ^